Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antibiotics-resistant lactic acid bacteria
- Development stage
- Unknown
- Lead developer
- Wakamoto
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Antibiotics-resistant lactic acid bacteria (marketed under the brand name Lebenin by Wakamoto Pharmaceutical) is a live biotherapeutic product consisting of three antibiotic-resistant bacterial strains: Bifidobacterium infantis, Lactobacillus acidophilus, and Streptococcus faecalis (Enterococcus faecalis). It is approved in Japan as a prescription drug to improve gastrointestinal symptoms and restore normal intestinal flora (dysbiosis) in patients undergoing treatment with antibiotics (such as penicillins, cephalosporins, aminoglycosides, macrolides, and tetracyclines) or chemotherapeutic agents (such as nalidixic acid). Because these strains are specifically cultured to be resistant to these antimicrobial agents, they can survive and proliferate in the gut during antibiotic therapy, producing lactic acid and other organic acids to inhibit the overgrowth of pathogenic bacteria and prevent antibiotic-associated diarrhea.
- Brand names
- BiofidinLebeninLebenin PowderLebenin Tablets
- Other names
- Antibiotics-Resistant Lactic Acid BacteriaeBifidobacterium infantis + Lactobacillus acidophilus + Enterococcus faecalisBifidobacterium infantis + Lactobacillus acidophilus + Streptococcus faecalis耐性乳酸菌
02
Targets
MUC2 (Mucin-2)PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on antibiotics-resistant lactic acid bacteria.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antibiotics-resistant lactic acid bacteria.